Search results
Results from the WOW.Com Content Network
Up to 20% of people taking isoniazid experience peripheral neuropathy when taking daily doses of 6 mg/kg of body weight or higher. [26] Gastrointestinal reactions include nausea and vomiting. [ 16 ] Aplastic anemia , thrombocytopenia , and agranulocytosis due to lack of production of red blood cells, platelets, and white blood cells by the bone ...
Ibuprofen, an analgesic and non-steroidal anti-inflammatory drug (NSAID), [1] is sold under many brand-names around the world. The most common are Brufen (its earliest registered trademark), Advil, Motrin, and Nurofen .
Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. [2] Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK [3] and a "Global Center" in Canonsburg ...
[20] A separate list for children up to 12 years of age, known as the WHO Model List of Essential Medicines for Children (EMLc), was created in 2007 and is in its 9th edition. [ 10 ] [ 21 ] [ 22 ] [ 23 ] It was created to make sure that the needs of children were systematically considered such as availability of proper formulations .
[citation needed] The drug was approved by the U.S. Food and Drug Administration (FDA) in June 1998. [8] [9] It is made from rifampicin. [medical citation needed] Rifapentine was granted orphan drug designation by the FDA in June 1995, [10] and by the European Commission in June 2010. [11]
AOL Mail welcomes Verizon customers to our safe and delightful email experience!
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania.The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
(Reuters) -The U.S. Food and Drug Administration has approved Ionis Pharmaceuticals' drug to treat a rare genetic disorder, making it the company's first wholly-owned drug, the health regulator's ...